Scientists have unveiled clues into why some cancer patients develop a serious heart condition after chemotherapy. The new research, from a team of international scientists led by Imperial College London, Royal Brompton Hospital and the MRC London Institute of Medical Sciences, shows the heart condition may be linked to a faulty gene called titin. In […]
A team of scientists led by Imperial College London have discovered a new strain of group A streptococcus bacteria. Group A streptococcus (or Strep A) is known to cause scarlet fever, throat infections and – in very rare cases – invasive disease, where the bacterium enters the bloodstream or tissue and can trigger sepsis and […]
Scientists have visualised for the first time protein ‘tangles’ associated with dementia in patients who have suffered a single head injury. This is the finding of a new study led by scientists from Imperial College London, published in the journal Science Translational Medicine. In the early-stage study, researchers studied 21 patients who had suffered a moderate to […]
Cancer patients on immunotherapy fare worse if they have recently taken antibiotics, with their response and overall survival rate ‘crashing’. The findings come from a study of almost 200 cancer patients in the UK taking a type of immunotherapy called checkpoint inhibitors, part of the standard treatment pathway for cancer patients on the NHS. Researchers […]
Are you a patient, carer, research or healthcare professional, or member of the public? Are you interested in clinical and health-related research? Visit our free Open Day to see demonstrations of the world-class science happening at Imperial The National Institute for Health Research (NIHR) is the largest funder of health and care research in the […]
Last month NIHR Imperial BRC welcomed Venture Capital investors Syncona at a pitching and networking event, organised by colleagues at Imperial’s Industry Partnerships and Commercialisation Team. Syncona is a life sciences investment company founded by the Wellcome Trust, and its goal is to build standalone healthcare companies that can deliver transformative treatments to patients. Their […]
Scientists have successfully used microneedle biosensors to accurately detect changes in antibiotic levels in the body for the first time. Small, non-invasive patches worn on the skin can accurately detect the levels of medication in a patient’s system, matching the accuracy of current clinical methods. In a small-scale clinical evaluation, researchers at Imperial College London […]
Harnessing world-leading discovery science and clinical expertise to develop innovative therapeutics, devices and diagnostics for healthcare
Examples of research projects testing out new drugs, devices and diagnostics in humans for the first time. The BRC is specifically aimed at supporting these kinds of experimental medicine studies.
The NIHR Imperial BRC has developed a range of innovative device technologies, in collaboration with scientists in our Faculties of Natural Sciences and Engineering. Some of the most recent are highlighted here.
The NIHR Imperial BRC has a strong, successful track record of collaborating with life sciences and other related industries, academic institutions, charities and research organisations. Most recent examples can be found here.